Delcath Systems, Inc. - Entwicklung nach Public Offering? - 500 Beiträge pro Seite

[Gustl24]

Delcath Systems, Inc. wurde nach kapitalbedarf
auf den public offering kurs zu $ 1,50 in den
letzten beiden tagen runterrasiert -
der kapitalbedarf war zwingend notwendig, da die firma dringend
"zeit" und cash bis zur anstehnden NDA-entscheidung in usa benötigt.

[Gustl24]

Antwort auf Beitrag Nr.: 43.225.616 von Gustl24 am 30.05.12 11:10:08

NEW YORK, May 25, 2012 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) today announced that it has priced an underwritten public offering of 13,333,340 shares of its common stock and warrants to purchase up to 4,000,002 shares of common stock at a combined price to the public of $1.50 per share and related warrant for gross proceeds of $20 million. The warrants are exercisable at an exercise price of $1.65 per share and will expire, unless exercised on the third anniversary of the date of issuance. The net proceeds from the sale of the shares and the related warrants, after deducting the underwriters' discounts and other estimated offering expenses payable by Delcath, will be approximately $18.4 million, which does not include any potential proceeds from the cash exercise of any warrants. Delcath has also granted the underwriters a 30-day option to purchase up to an additional 15 percent of shares of common stock and warrants offered in the public offering to cover over-allotments, if any, which would result in additional gross proceeds of approximately $3 million, if exercised in full.

The proceeds of the offering will primarily be used for general corporate purposes, including, but not limited to, commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, research, capital expenditures and working capital. The offering is expected to close on or about May 31, 2012, subject to the satisfaction of customary closing conditions.

Source: PR Newswire

[Gustl24]

Antwort auf Beitrag Nr.: 43.225.630 von Gustl24 am 30.05.12 11:12:55

About Delcath Systems
Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath announced that its randomized Phase III clinical trial for patients with metastatic melanoma in the liver had successfully achieved the study's primary endpoint of extended hepatic progression-free survival. The Company also completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Delcath Hepatic CHEMOSAT® delivery system in April 2011 and for the second generation hemofiltration cartridge for CHEMOSAT in April 2012. The right to affix the CE mark allows the Company to market and sell the CHEMOSAT system in Europe. The Company has not yet received FDA approval for commercial sale of its system in the United States. The Company continues with the preparation of its NDA submission and intends to seek FDA approval for commercial sale of its chemosaturation system with melphalan. For more information, please visit the Company's website at www.delcath.com.

Source: PR Newswire (http://s.tt/1cKpo)

[Gustl24]

Antwort auf Beitrag Nr.: 43.225.642 von Gustl24 am 30.05.12 11:15:16

das lead-produkt ist in europa zugelassen und wird auch in dt. Zentren
angewendet:

Delcath Systems, Inc. Receives European Regulatory Approval For Second Generation Hemofiltration Cartridge

Thursday, 5 Apr 2012 06:00am EDT
Delcath Systems, Inc. announced that the Company has received CE Mark approval for the second generation hemofiltration cartridge of the Company's proprietary Hepatic CHEMOSAT Delivery System. With the new hemofiltration cartridge, the CHEMOSAT system carries the same broad indication as the previous generation system, permitting physicians to use the product for the percutaneous intra-arterial administration of a chemotherapeutic agent (melphalan hydrochloride) to the liver to any patient who in their opinion may benefit.

[Gustl24]

Antwort auf Beitrag Nr.: 43.225.679 von Gustl24 am 30.05.12 11:20:58

ich bin vorgestern zu $ 1,50 an der NASDAQ eingestiegen -
kurs wird nur in USA gemacht...in sofern kein leidlicher
push-versuch in old germany...ich handele diese aktien nur an der NASDAQ
über meinen broker...

bitte den heutigen premarket-kurs der NASDAQ nicht beachten...muss
irgendein "verrückter" pusher mit kleinen stückzahlen sein...

NDA entscheidung sollte binnen der nächsten 3 monate kommen...
die verwendung des lead-produkts an ren. europ. zentren
sollte "kein nachteil sein"...problem der firma - der kurs kommt
von $ 15 !! - ist der stetige kapitalschwund und der wettlauf
bis zur FDA-entscheidung...

aber zu heutigen kursen für mich ein vertretbares mittelfristiges
risiko-biotech-investment!!

jetzt feuer frei für eure diskussion!

[Gustl24]

Antwort auf Beitrag Nr.: 43.225.728 von Gustl24 am 30.05.12 11:28:33

kein interesse an dieser aktie - gut...jeden tag 3% plus reichen mir...

einstieg jetzt im mittel unter $ 1,50 bei 12 k stücke...

[McNay]

Ich beobachte Delcath aktuell auch. Beim Bruch der 3 Dollar-Marke bin ich damals raus. Was mich stört ist, warum das Management nicht eher gehandelt hat, sondern bei einem Kurs von 2,20 neue Aktien zu 1,50 ausgibt. Das bis zur FDA-Entscheidung noch eine Kapitalerhöhung nötig war, wußte jeder schon im Januar als der Kurs noch bei 4 Dollar war.
Würde mich nicht wundern, wenn wir im Sommer die 1,20 sehen.
Sicherlich wenn die FDA-Zulassung kommt, sind hier locker 5-6 Dollar drin...
aktuell in diesem Marktumfeld ist mir ganze aber zu heiß.

[Gustl24]

Antwort auf Beitrag Nr.: 43.266.938 von McNay am 09.06.12 14:13:50

geht jetzt los